[1]李晓春,侯艳红.国家基本药物制度的完善及走向[J].卫生经济研究,2018,(12):34-36.
　LI Xiao-chun,HOU Yan-hong.The Improvement and Trend of the National Basic Drug System[J].Journal Press of Health Economics Research,2018,(12):34-36.
点击复制

国家基本药物制度的完善及走向
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年12期
页码:
34-36
栏目:
药械管理
出版日期:
2018-12-04

文章信息/Info

Title:
The Improvement and Trend of the National Basic Drug System
作者:
李晓春1; 侯艳红1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
LI Xiao-chun;  HOU Yan-hong
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
基本药物制度; 基本药物目录; 免费供应; 分类管理
Keywords:
basic drug system;  catalogue of basic drugs;  free supply;  classified management
分类号:
R95
文献标志码:
A
摘要:
从目录、特点和供应保障三个方面分析我国基本药物制度存在的不完善之处，并借鉴国外对基本药物目录遴选和分类管理的做法，以及推行基本药物免费供应等经验，建议我国从建立基本药物分目录、探索基本药物免费供应等方面入手，在顶层设计的宏观导向下，充分发挥基本药物制度优势，最终实现“人人享有公平可及的医疗卫生服务”的目标。
Abstract:
From the aspects of catalogue, characteristics and supply guarantee, this paper analyzed the imperfections of China's basic drug system, and learned from foreign experiences in the selection and classification management of basic drugs, as well as the implementation of free supply of basic drugs.This paper suggested that China should start from establishing the sub-category of basic drugs and exploring the free supply of basic drugs and give full play to the advantages of the basic drug system and finally achieve the goal of "everyone has access to fair and accessible medical and health services" under the macro-level design of the top-level design.

参考文献/References:

[1] 常峰,李思函. 基本药物统一定价可行性分析[J]. 中国药物评价,2013（2）:117-120，128.
[2] 刘扬. 澳大利亚药品津贴计划及其对完善我国基本药物监管方式的启示[J]. 卫生软科学,2013，27（12）:756-759.
[3] 肖宏浩,郭振华,饶晓兵. 澳大利亚的经验对我国基本药物目录遴选的启示[J]. 中国药事,2008（11）:961-963，968.
[4] 王莉，周帮旻，宋佳佳，等.25国基本药物目录征询评价[J].China J Evid-based Med，2009，9（7）：754-764.
[5] Chaudhury R.R, Parameswar R, Gupta U,et al.Quality medicines for the poor: Experience of the Delhi program on rational use of drugs[J].Health Policy and Planning, 2005, 20 (2): 124-136.
[6] Cohen J.C, Montoya J.Using technology to fight corruption in pharmaceutical purchasing: lessons learned from the Chilean experience. Washington, DC: World Bank Institute, 2001.
[7] 常峰,杨莎莎,路云. 基于网络分析法的基本药物制度监测评价指标体系构建[J]. 中国卫生事业管理,2015,32（12）:918-921.

相似文献/References:

[1]王 鑫,王艳翚.基本药物制度与基本医疗保险制度的衔接研究[J].卫生经济研究,2017,(10):7.
[2]路 云,张闪闪,李世勇.江苏省基本药物制度实施效果评价与思考[J].卫生经济研究,2017,(10):45.
[3]裴 婕,路 云,周 萍,等.瑞典基本药物目录的发展及启示[J].卫生经济研究,2018,(08):46.
　PEI Jie,LU Yun,ZHOU Ping,et al.The development and enlightenment of essential drug list in Sweden[J].Journal Press of Health Economics Research,2018,(12):46.
[4]胡善联.2019年版世界卫生组织 基本药物目录的创新及特点[J].卫生经济研究,2019,(09):3.
　HU Shan-lian.Innovation and Characteristics of WHO Essential Medicines Model List 2019[J].Journal Press of Health Economics Research,2019,(12):3.

更新日期/Last Update: 2018-12-04